The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance.
about
AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocationComputer aided analysis of additional chromosome aberrations in Philadelphia chromosome positive acute lymphoblastic leukaemia using a simplified computer readable cytogenetic notationZebrafish Models of Human Leukemia: Technological Advances and Mechanistic InsightsMTG8 proto-oncoprotein interacts with the regulatory subunit of type II cyclic AMP-dependent protein kinase in lymphocytesThe transcriptional corepressor MTG16a contains a novel nucleolar targeting sequence deranged in t (16; 21)-positive myeloid malignanciesThe ENL moiety of the childhood leukemia-associated MLL-ENL oncoprotein recruits human Polycomb 3Identification of single- and multiple-class specific signature genes from gene expression profiles by group marker indexHoxB8 requires its Pbx-interaction motif to block differentiation of primary myeloid progenitors and of most cell line models of myeloid differentiation.The human SIN3B corepressor forms a nucleolar complex with leukemia-associated ETO homologuest(8;21)(q22;q22) Fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression.The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.The genomic landscape of core-binding factor acute myeloid leukemiasBiological characteristics of the leukemia-associated transcriptional factor AML1 disclosed by hematopoietic rescue of AML1-deficient embryonic stem cells by using a knock-in strategy.Dichotomy of AML1-ETO functions: growth arrest versus block of differentiationThe management of neoplastic disorders of haematopoiesis in children with Down's syndrome.Transcription therapy for acute promyelocytic leukaemia.Folylpolyglutamate synthetase gene transcription is regulated by a multiprotein complex that binds the TEL-AML1 fusion in acute lymphoblastic leukemia.Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network.Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins.Common themes in the pathogenesis of acute myeloid leukemia.Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemiaCore binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?Leukaemia -- a developmental perspective.Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.RNA interference as a potential tool in the treatment of leukaemia.Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO.Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndromeTargeting leukemic fusion proteins with small interfering RNAs: recent advances and therapeutic potentials.Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genesRoles of p15Ink4b and p16Ink4a in myeloid differentiation and RUNX1-ETO-associated acute myeloid leukemiaChaperonin TRiC/CCT Modulates the Folding and Activity of Leukemogenic Fusion Oncoprotein AML1-ETO.Chaperonin TRiC/CCT Recognizes Fusion Oncoprotein AML1-ETO through Subunit-Specific Interactions.Helicase-like transcription factor is a RUNX1 target whose downregulation promotes genomic instability and correlates with complex cytogenetic features in acute myeloid leukemia.Amplification and thrifty single-molecule sequencing of recurrent somatic structural variations.Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice.New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia.The E2A-HLF oncoprotein activates Groucho-related genes and suppresses Runx1.
P2860
Q24681049-55DC855F-381E-4949-9480-241C38992F4BQ24798120-6E878C48-E3DD-4032-B893-269C88890325Q28078210-6F2F420C-0DA0-401F-B468-89BF8A391DD5Q28191156-AD0E5F09-8494-499F-A48C-339DAFECE00BQ28202877-2850B595-784B-44F3-A8FF-FBEBC355C75EQ28213852-9859484C-EC69-4870-9276-86EBAE3D1E55Q28476766-6A2DA92D-7CAD-4866-982E-997180EBF520Q30176411-9A63296F-3AA8-493F-8424-4376A803B97AQ33315477-32DB69BF-4FFB-4AB0-BDF5-0BA715048E7DQ33338784-3A1C480D-B836-459E-83DC-A85C47294987Q33895709-0E5AA076-A121-4059-B82E-3C551A511CD6Q33901968-B11C6B41-92BD-4906-A41F-9693A1F88A96Q33961306-93FEFB5D-E636-4F31-9CA3-28B5CE73A3F7Q33969245-DABCFF2A-00AB-4FC5-B04B-934FBC9AE798Q34039933-2E2CBED0-ED63-40B9-B2B5-91A2E573F261Q34074712-71628246-D850-474E-8470-EB253E34E3A4Q34161064-AFB6E3A0-8F10-473E-AECF-F5B90417E3E1Q34372000-98AB55C9-E118-4BEC-8935-B9AF3ECEABC5Q34386755-FE0645FE-0BDC-43B3-9BE8-01F189EC9762Q34405458-96D6D3AB-3141-4D64-8307-BA7F491E3415Q35168360-047A4652-3F79-4FF0-8A5F-53B0A834E9F7Q35203844-DF087D04-4C07-4509-99B5-A251219284C8Q35805989-828EFF4F-18B9-4200-AC7B-967C244FB056Q35937101-E2EF1E1D-754D-46AF-A7CD-754D5966DAECQ35967287-93D6421D-F1F8-48C2-AA93-D46CFDD90842Q36102812-3AB44979-0808-4198-BE46-616CB20F2C5DQ36384719-55CCA58C-749B-4C71-8D93-D00978F55167Q36401746-BDE89A2A-1288-441B-BDDB-C356ADD00A0BQ36422351-545C3540-8B58-4E76-A275-20D42322712CQ36710850-5426BA24-8722-45D3-908F-AE1D2616A4DCQ36724840-CA49E6C9-4D57-42F0-9212-042405736ECDQ36744579-F342529C-5AAA-4471-BACA-7C14210D7A78Q37000704-81E5F1E7-DF6F-46B5-9E5D-8421CABAE7A8Q37216297-758E8902-116F-4A8A-9B59-090B938A267EQ37550251-EA14D997-BE29-4EA1-A789-43C1F36CE7C4Q37589404-430D0242-0AA0-452F-908B-B594943D7853Q37679748-58E3133F-35DD-457F-BD66-AD14CD90CA57Q38196743-8BD735F6-B735-4FA7-82CD-6A0A034EE95CQ39181108-A1EF7287-05B0-484B-AF13-1F0E4B58A6A7Q39460862-BFD7CC46-3349-4D0F-85DE-F397CC1DF760
P2860
The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The AML1-ETO chimaeric transcr ...... ogy and clinical significance.
@ast
The AML1-ETO chimaeric transcr ...... ogy and clinical significance.
@en
type
label
The AML1-ETO chimaeric transcr ...... ogy and clinical significance.
@ast
The AML1-ETO chimaeric transcr ...... ogy and clinical significance.
@en
prefLabel
The AML1-ETO chimaeric transcr ...... ogy and clinical significance.
@ast
The AML1-ETO chimaeric transcr ...... ogy and clinical significance.
@en
P2860
P1476
The AML1-ETO chimaeric transcr ...... ogy and clinical significance.
@en
P2093
Downing JR
P2860
P304
P356
10.1046/J.1365-2141.1999.01377.X
P407
P577
1999-08-01T00:00:00Z